article thumbnail

Drug made from pig intestine helps escape the “trap” of clot-causing immune response

Scienmag

When the body attempts to fight off an infection, immune cells called neutrophils may shoot out spider web-like networks of toxic proteins to help contain the invaders. Latest News clotcausing Drug escape helps immune intestine pig response trapHowever, when not properly regulated, these web-like neutrophil extracellular traps, or NETs, play a role in forming blood clots and promoting inflammation for several diseases, including COVID-19. Utilizing […].

article thumbnail

New research will allow convenient investigation of human innate immune response to viral infections

Scienmag

(Boston)–Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

Reagent 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vitamin E from palm oil useful in boosting immune response based on studies on liver cells

Scienmag

The article by Dr. Ahmed Atia and colleagues is published in Current Pharmaceutical Biotechnology, 2020 Palm oil contains abundant quantities of vitamin E compounds, which include tocopherols and tocotrienols. These compounds have anti-oxidant effects, which protect cells from damage from toxic chemical produced by metabolic processes. While tocopherol is a widely known and researched compound, […].

article thumbnail

Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose

The Pharma Data

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.

article thumbnail

Long-term COVID-19 containment will be shaped by strength, duration of immunity

Scienmag

Credit: Tumisu from Pixabay New research suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19.

article thumbnail

ESMO 2022: the evolution of TIL therapy – a highly promising approach

Pharmaceutical Technology

Before TIL infusion, the patient undergoes lymphodepletion, which reduces the proportion of myeloid immune suppressive cells and creates space for the incoming lymphocytes. The overall response rate (ORR) for TILs was 48.8% for Yervoy, with complete response (CR) rates of 20.2%

article thumbnail

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Pharmaceutical Technology

The updated, Omicron-containing bivalent vaccine that acts on two coronavirus variants is indicated as a booster dose for active immunisation for the prevention of Covid-19 in people of this age group.

article thumbnail

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

According to CEPI: “Achieving the 100 Days Mission would give the world a fighting chance of containing a future outbreak before it spreads to become a global pandemic.”. billion towards the “pandemic-busting plan”, which involves the investigation of rapid response vaccine technologies.

RNA 130
article thumbnail

Lifileucel, what is the likelihood that the drug will be approved?

Pharmaceutical Technology

It is developed as a ready to infuse autologous cellular immunotherapy product and contains adoptive cellular immunotherapy regimen. The therapeutic candidate consists of autologous tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor further expanded and then infused back to the patient enabling the patient robust immune response. Lifileucel is under clinical development by Iovance Biotherapeutics and currently in the Phase II in clinical pathway.

article thumbnail

Scans Reveal How COVID-19 Can Harm the Brain

The Pharma Data

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. THURSDAY, Dec.

article thumbnail

Fighting viruses is as easy as breathing

The Pharma Data

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses.

article thumbnail

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

The Pharma Data

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). 1, 2021 12:05 UTC.

article thumbnail

As gonorrhoea threat grows, Intravacc gets $14m for vaccine hunt

Pharma Phorum

Called NGoXIM, the vaccine is based on gonococcal OMVs combined with sustained-release microspheres containing recombinant human IL-12, supplied Intravacc’s US partner Therapyx, which are designed to boost the immune response to the antigens.

article thumbnail

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

An application submitted under 351(a), also known as a “stand-alone” application, must contain all safety and effectiveness information for a biological product and cannot depend on any other biological product.

article thumbnail

U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

The Pharma Data

Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for important disease-causing shared serotype 3 and unique serotypes 22F and 33F compared to PCV13.

article thumbnail

Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

The Pharma Data

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by the S.

article thumbnail

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

The Pharma Data

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.

article thumbnail

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

The Omicron variant spreads more easily than earlier variants of the virus that cause Covid-19, including the Delta variant, and also has the ability to sometimes evade immunity from vaccines, previous infection, or both.

article thumbnail

Myeloid cell targeting therapeutics: Budding therapy against cancer

Roots Analysis

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity.

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

He explained that by taking the vaccine orally “allows for a mucosal response in the intestine that can trigger signals to eliminate viruses in the body.”. Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

article thumbnail

AZ resumes trial of COVID-19 vaccine

The Pharma Data

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The move follows a green light by the UK's MHRA.

article thumbnail

Moderna Reveals Positive Results for its mRNA Influenza Vaccine

XTalks

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus.

article thumbnail

Flow cytometry: advantages in immunotherapy clinical trials

Pharmaceutical Technology

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. It’s used primarily to monitor changes in immune cell phenotype, to monitor therapeutic cells, and to detect and monitor abnormal cells.

article thumbnail

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate

The Pharma Data

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults.

article thumbnail

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. GAITHERSBURG, Md., 16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc.

article thumbnail

Is Probiotic Soda Actually Healthy and Which Companies Produce It?

XTalks

Simply put, probiotic sodas are carbonated drinks that contain one or more probiotic ingredient(s). They can also help your body maintain a healthy community of microorganisms, produce substances that have desirable effects and influence your body’s immune response.

article thumbnail

Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy

XTalks

Moreover, a very strong immune response is needed to fend off the disease. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax.

article thumbnail

What Do We Really Know About Macrophage Programming?

XTalks

The anti-inflammatory macrophages help in preventing an immune response from becoming dangerous, as seen with patients with autoimmune disease. This helps to ensure that inflammation naturally subsides after the initial immune response and promotes tissue repair.

article thumbnail

MYELOID CELL TARGETING THERAPEUTICS: BUDDING THERAPY AGAINST CANCER

Roots Analysis

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity.

article thumbnail

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

The Pharma Data

The much more infectious SARS-CoV-2 continues to infect people and damage communities and economies worldwide, with new variants of concern emerging successively, and Omicron evading vaccination and immune response. ” Omicron has undergone many mutations, enabling it to escape immune protection offered by vaccination or antibody treatments that lag behind this rapidly evolving virus.

Protein 63
article thumbnail

Rome Therapeutics raises $77m for junk DNA-targeting drugs

Pharma Phorum

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.

Genome 52
article thumbnail

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

The Pharma Data

Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses [1]. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners.

article thumbnail

For Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID Shot

The Pharma Data

An Ohio State University review of 49 vaccine studies dating back 30 years examined how stress, depression and healthy behaviors, such as exercise, can affect immune response to a vaccine. ” Past research has shown a variety of ways that immune response can be hampered.

article thumbnail

Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis

The Pharma Data

BTK inhibitors are a novel class of therapies that target B-cells and other innate immune cells and prevent inflammation and potentially disease progression in MS.

article thumbnail

Keeping tabs on Covid-19: Thermo Fisher Scientific antibody test is granted the CE Mark Certification and pharma cargo companies prepare for temperature-controlled vaccine delivery

The Pharma Data

More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

article thumbnail

Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma

The Pharma Data

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. The interim results of our monotherapy cohorts suggest SYNB1891 is working as designed, upregulating the immune system in the tumor microenvironment via the STING pathway.

article thumbnail

FDA fast-tracks Leap’s gastric cancer immunotherapy

Pharma Phorum

DKN-01 is an antibody drug targeting the Dickkopf-1 (DKK1) protein, which is overexpressed in some forms of G/GEJ adenocarcinoma and is thought to be involved in tumour growth as well as dampening down the immune response against the cancer. In animal models, neutralising DKK1 has been shown to activate an innate immune response against malignant cells.

article thumbnail

Great News from EMA in December: Three New Treatments for COVID-19

CATO Research

Treatment with dexamethasone (corticosteroid) containing products with earlier marketing authorizations in EU member states was endorsed by the EMA in September 2020 for this population and has become a standard of care. Targeting Immune Response. Overreaction of the immune system, hyperinflammation (sometimes called “cytokine storm”), is believed to be part of the pathogenetic mechanism leading to respiratory failure in patients critically ill with COVID-19.

article thumbnail

AZ expands phase 3 trials of COVID-19 vaccine frontrunner into US

Pharma Phorum

The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups.

article thumbnail

Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response

The Pharma Data

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D.,

article thumbnail

WHO Grants Novavax’s COVID-19 Vaccine Covovax Emergency Use Listing

XTalks

It contains Novavax’s Matrix-M adjuvant to enhance the immune response. The World Health Organization (WHO) has backed Novavax’s COVID-19 vaccine, Covovax (NVX-CoV2373), by granting it an emergency use listing (EUL).

Protein 81
article thumbnail

Vaxzevria approved in the EU as third dose booster against COVID-19

The Pharma Data

Ensuring a longer duration of immune protection is essential to the long-term management of COVID-19 globally, and boosters can address the waning of protection over time that has been seen with all primary vaccine schedules to date.”

article thumbnail

New COVID Variants May Weaken Vaccines, But Shots Will Still Protect You: Experts

The Pharma Data

“It gives the virus a chance to adapt to the forces, in this case the immune response, that are trying to get rid of it, and that’s why you get mutations.” Herd immunity harder to reach. FRIDAY, Jan.